Maȷor Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients [Epidemiology]

ConclusionsIn a real‐world cohort of nonvalvular atrial fibrillation patients, apixaban had a lower adjusted major bleeding risk compared with rivaroxaban, dabigatran, and warfarin. Apixaban had a lower risk of nonpersistence compared with dabigatran and warfarin and similar risk compared with rivaroxaban.

http://jaha.ahajournals.org/content/6/2/e004517.short?rss=1

Source: JAHA:Journal of the American Heart Association - February 14, 2017 Category: Cardiology Authors: Lamberts, M., Staerk, L., Olesen, J. B., Fosbol, E. L., Hansen, M. L., Harboe, L., Lefevre, C., Evans, D., Gislason, G. H. Tags: Atrial Fibrillation, Epidemiology, Anticoagulants, Complications Original Research Source Type: research

Ma&#x0237;or Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients [Epidemiology]

Maȷor Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients [Epidemiology]